Navigation Links
Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy

SEATTLE, Dec. 6 /PRNewswire-FirstCall/ -- Results from RESTORE 2, a placebo-controlled, Phase III study demonstrated that the investigational compound retigabine significantly reduced the number of seizures in adult patients with refractory partial-onset epilepsy when a 600 mg or 900 mg dose was added to a patient's current anti-epileptic drug (AED) therapy. Prior to enrollment in the retigabine clinical trials, patients were experiencing seizures despite taking stable doses of up to three AEDs.

Retigabine has a different mechanism of action than currently approved AEDs. Retigabine is a neuronal potassium channel opener, which helps control neuronal excitability. In epilepsy patients, brain cells can become overly excited, disrupting normal brain activity and causing seizures.

"Approximately 30 percent of epilepsy patients are not well-controlled despite treatment with existing anti-epileptic drugs," said Jacqueline A. French, M.D., Professor of Neurology, New York University Medical Center and an investigator in the study. "Many of the currently available AEDs regulate sodium channels or calcium channels in the brain to help reduce seizures. Given the unmet medical need, it is hoped that medications with novel mechanisms of action, like retigabine, will improve outcomes in patients with refractory epilepsy."

The RESTORE 2 study results were presented at the 62nd Annual Meeting of the American Epilepsy Society in Seattle on Saturday December 6, 2008. In addition to the Phase III results, five other studies of retigabine were presented at AES.

About the Clinical Trials

The Phase III program for retigabine consisted of two randomized, double- blind, placebo-controlled, multi-center, parallel-group studies that assessed the efficacy, safety and tolerability of retigabine as an adjunctive treatment for adult epilepsy patients with refractory partial-onset seizures. The program, called RESTORE (Retigabine Efficacy and Safety Trial for Partial- Onset Epilepsy) 1 and 2, involved approximately 120 sites in more than 17 countries worldwide.

RESTORE 1 evaluated a 1200 mg daily dose of retigabine (the highest dose in the Phase III program) versus placebo, while RESTORE 2 evaluated 600 mg and 900 mg daily doses of retigabine versus placebo. In these studies, retigabine demonstrated a statistically significant reduction in seizures compared to placebo at all three doses when added to patients' current AED therapy. Additionally, RESTORE 2 showed a dose-dependent response when the dose of retigabine was increased from 600 mg to 900 mg daily.

Tolerability of retigabine was generally dose-dependent. The most common side effects associated with retigabine in the RESTORE trials occurring in greater than or equal to 10 percent of patients included dizziness, somnolence, fatigue, confusion, dysarthria (slurred speech), ataxia (loss of muscle coordination), urinary tract infection, blurred vision, tremor, and nausea. Urinary bladder effects, while monitored during the studies, were uncommonly reported.

GlaxoSmithKline (NYSE: GSK) (LSE: GSK) and Valeant Pharmaceuticals International (NYSE: VRX) entered into an exclusive worldwide collaboration agreement for retigabine earlier this year. The companies plan to file a New Drug Application in the United States and a Marketing Authorization Application in Europe in 2009.

About Epilepsy

Epilepsy, defined by recurrent, unprovoked seizures, is a change in sensation, awareness or behavior caused by an electrical disturbance in the brain. The kind of seizure a person has depends on which part and how much of the brain is affected by the disturbance. Primary generalized seizures involve the entire brain from the outset, while partial-onset seizures begin in a focal area of the cerebral cortex. In most cases, however, the cause of epilepsy is unknown.

Epilepsy affects more than 50 million people worldwide, including 3 million Americans. Approximately 30 percent of epilepsy patients are not adequately controlled with currently prescribed AEDs.

About GlaxoSmithKline

One of the world's leading research-based pharmaceutical and healthcare companies, GSK is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit

About Valeant

Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at


     GSK US Media inquiries:                Robin Gaitens     (919) 483 2839
                                            Holly Russell     (919) 483 2839

     GSK US Analyst/ Investor inquiries:    Tom Curry         (215) 751 5419

     Valeant Media and Investor inquiries:  Laurie W. Little  (949) 461 6002

GSK cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2007.

Valeant Pharmaceuticals forward-looking statements

This press release contains forward-looking statements, including, but not limited to, statements regarding expectations or plans of development program for retigabine and the potential role retigabine could play in managing epilepsy and in treating other indications, and the commercial opportunity retigabine may present for Valeant. These statements are based upon the current expectations and beliefs of Valeant's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to the clinical development of retigabine, the fact that adverse events are not always immediately apparent even in well designed clinical trials, regulatory approval processes, the potential that competitors may bring to market drugs or treatments that are more effective of more commercially attractive than retigabine, and other risks and uncertainties discussed in the company's filings with the SEC. Valeant wishes to caution the reader that these factors are among the factors that could cause actual results to differ materially from the expectations described in the forward- looking statements. Valeant also cautions the reader that undue reliance should not be placed on any of the forward-looking statements, which speak only as of the date of this release. The company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this release or to reflect actual outcomes.

    Registered in England & Wales:
    No. 3888792

    Registered Office:
    980 Great West Road
    Brentford, Middlesex
    TW8 9GS

SOURCE GlaxoSmithKline; Valeant Pharmaceuticals International
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome
2. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
3. Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
4. Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
5. ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
6. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
7. Successful Results for Mymetics Corporations Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations
8. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
9. Hibernation-On-Demand Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss
10. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
11. New Study: Pine Bark Significantly Reduces Menstrual Pain
Post Your Comments:
(Date:11/30/2015)... Belgium , Nov. 30, 2015   ... focused on developing blood-based diagnostic tests for a broad range ... will present at the LD Micro Conference, which will be ... CA. Attending from VolitionRx will be David ... Powell , Vice President of Investor Relations. ® ...
(Date:11/30/2015)... IRVINE, Calif. and REHOVOT, Israel ... privately held specialty pharmaceutical company focused on acquiring and ... disorders, today announced the appointment of Keith A. ... directors. Gregory J. Flesher , chief executive ... experience in building successful organizations.  As chairman, he will ...
(Date:11/29/2015)... 2015   Royal Philips  (NYSE: PHG, AEX: PHIA) ... the 2015 Radiological Society of North America Annual Meeting ... in Chicago . Visitors to the ... broad portfolio of integrated Diagnostic Imaging, Clinical Informatics, Image ... performance, improve workflow and create a superior patient experience. ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... ... It’s inevitable that everyone will experience death in his or her lifetime. ... lives among us. It is your perspective, however, that determines how you view death ... T Sky understands that she may see death more frequently than most. As she ...
(Date:11/30/2015)... ... November 30, 2015 , ... Sikka Software announced today that ... Their Ecosystem empowers dentists to make complex business decisions by providing the tools and ... a free fee survey with 10 procedures customized by zip code. , The ...
(Date:11/30/2015)... ... 30, 2015 , ... Insightra Medical, Inc. and Novus Scientific ... for soft tissue repair in the US via Insightra’s national direct sales channel. ... intended to support and reinforce soft tissue for 6-9 months before absorbing completely ...
(Date:11/30/2015)... Columbia, Maryland (PRWEB) , ... November 30, 2015 ... ... human interactions could be of critical importance to the medical schools of the ... SIMmersion exhibited its healthcare suite at the 2015 ChangeMedEd conference in Chicago, organized ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... a leading provider of enterprise Time and Attendance/Workforce Management cloud-based solutions, announced ... Microsoft Partner Program with competencies in the Application Development, demonstrating a “best-in-class” ...
Breaking Medicine News(10 mins):